Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001

Nephrology

Volumn 8, Issue 4, 2003, Pages 177-183

  Chow, Fiona Y F ^a   Polkinghorne, Kevan R ^a   Chadban, Steven J ^a   Atkins, Robert C ^a   Kerr, Peter G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Cardiovascular disease; Chronic renal failure; Diabetes; Hyperlipidaemia; Hypertension; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG USE; FEMALE; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0041662174     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2003.00157.x     Document Type: Article

References (28)

1. US Renal Data System. USRDS 2001 Annual Data Report. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
3. Hjalmarson A, Herlitz J, Holmberg S et al. The Goteborg Metoprolol Trial. Circulation 1983; 62: 26-32.
4. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 1996; 335: 1001-9.
6. Yusuf S, Sleight P, Pogue J et al. The Heart Outcomes Prevention Evaluation Investigators: effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N. Engl. J. Med. 2000; 342: 145-53.
7. Pfeffer MA, McMurray J, Leizorovicz A et al. Valasartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and Design. Am. Heart J. 2000; 140: 727-50.
8. Tonelli M, Bohm C, Padeya S, Gill J, Levin A, Kiberd B. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am. J. Kidney Dis. 2001; 37: 484-9.
9. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol. Dial. Transplant. 1994; 9: 1136-42.
10. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin. Nephrol. 2001; 56: 221-30.
11. Mailloux L, Levey A. Hypertension in patients with chronic renal disease. Am. J. Kidney Dis. 1998; 32 (Suppl. 3): S120-41.
12. Zager PG, Nikolic J, Brown RH et al. 'U' Curve association of blood pressure and mortality in haemodialysis patients. Kidney Int. 1998; 54: 561-9.
13. Degoulet P, Legrain M, Reach I et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31: 103-10.
14. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int. 1999; 56: 1136-48.
15. Nishizawa Y, Shoji T, Ishimura E et al. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am. J. Kidney Dis. 2001; 38 (Suppl. 1): S4-7.
16. Jardine AG, McLaughlin K. Cardiovascular complications of renal disease. Heart 2000; 86: 459-66.
17. Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriopathy (calciphylaxis). Curr. Opin. Nephrol. Hypertens. 2001; 10: 741-7.
18. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000; 58: 353-62.
19. US Renal Data System. Comorbid conditions and correlations with mortality risk among 3399 incident hemodialysis patients. Am. J. Kidney Dis. 1992; 20: 32-8.
20. Seliger S, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61: 297-304.
21. Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: 1113-17.
22. Cannella G, Paoletti E, Delfino R et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int. 1993; 44: 881-6.
23. Cannella G, Paoletti E, Delfino R et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am. J. Kidney Dis. 1997; 30: 659.
24. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36: 286-90.
25. Disney APS, ed. ANZDATA Registry Report 2000, Mortality section. Adelaide: Australia and New Zealand Dialysis and Transplant Registry, 2001; 35.
26. Miscellaneous. Clinical algorithms on cardiovascular risk factors in renal patients. Nephrol. Dial. Transplant. 2000; 15 (Suppl. 5): S123-54.
27. Silberberg JS, Rahal DP, Patton DR, Sniderman DR. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am. J. Cardiol. 1989; 64: 222-4.
28. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37-43.